Advances in blocking NRP1 interactions, particularly in the VEGF pathway, demonstrate the druggability of this receptor.[51] Together, these insights offer a structural and pharmacological basis for developing novel therapies aimed at restoring pigmentation in disorders such as vitiligo or post‐inflammatory hypopigmentation, where reactivating melanocyte function is essential for effective re‐pigmentation. The gene discussed is NRP1; the disease is vitiligo.